1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Evotec SE

Evotec SE

EVT.SW
Evotec SECH flagSwiss Exchange
5.04
EUR
+0.03
- -
892.67MMarket Cap
Evotec SE
EVT.SW
(Swiss Exchange)

Recent

price

5.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.25
4.42
4.5
4.44
4.19
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.99
-0.47
-1.11
-0.58
-1.09
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.14
-1.01
-0.64
-0.52
-0.3
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.22
-1.69
-2.79
-3.37
-4.05
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.03
4.68
3.63
2.87
2.22
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
177
177
177
178
178
Basic Weighted Avg Shares
55
80
87
86
89
128
165
264
375
446
501
618
751
781
797
788
745
Sales/Revenue/Turnover
-5.1
7.19
0.35
4.85
2.24
-1.98
22.34
13.22
17.69
16.72
10.34
6.74
2.77
-3.41
-9.9
-7.08
-11.06
Operating Margin (%)
6
6
9
9
9
12
12
21
31
49
56
70
83
93
102
99
- -
Depreciation Expense
3
7
2
-25
-7
17
28
23
84
38
6
216
-176
-84
-196
-104
-194
Net Income, GAAP
22.81
- -
- -
- -
- -
- -
18.55
9.18
- -
34.16
75.7
9.06
- -
- -
- -
- -
50.37
Effective Tax Rate (%)
5.9
8.42
2.84
-29.59
-7.8
12.94
16.73
8.9
22.42
8.55
1.25
34.87
-23.38
-10.74
-24.6
-13.13
-26.02
Profit Margin (%)
54
38
54
84
92
111
96
-65
53
291
450
776
736
439
337
395
288
Working Capital
4
2
4
- -
8
9
7
21
58
442
462
462
490
477
393
344
299
LT Debt
133
147
153
159
158
187
214
332
425
477
724
1,378
1,187
1,120
953
814
700
Total Equity
-1.6
- -
- -
- -
- -
- -
13.19
8.26
- -
6.6
1.16
2.43
- -
- -
- -
- -
- -
Return on Invested Capital (%)
-0.86
- -
- -
- -
- -
- -
-6.58
-7.56
- -
-200.57
4.21
64.31
- -
- -
- -
- -
43.04
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
89
LT Borrowings
- -
344
299
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
178
177
178
Market Capitalization
- -
- -
684

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
793
763
711
Cash, Cash Equivalents & STI
243
463
464
Accounts Receivable, Net
104
136
98
Inventories
31
29
33
Total Current Liabilities
374
368
423
Payables & Accruals
57
81
64
ST Debt
- -
- -
89
Deferred Revenue
110
108
115

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.28%
8.23%
-14.57%
Free Cash Flow
-233.81%
-156.96%
-19.48%
Net Income, GAAP
335.78%
637.1%
-47.21%
Sales/Revenue/Turnover
21.25%
9.97%
-1.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
209
182
185
221
797
2025
200
171
164
253
788
2026
157
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.54
-0.22
- -
-1.11
2025
-0.18
-0.24
-0.24
- -
-0.58
2026
-0.69
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Fagron N.V. (ARSUF)
Industry Source Consulting, Inc. (INSO)
Bioray Biotech Co., Ltd (7561.TWO)
Mercury Biopharmaceutical Corporation (6932.TWO)
Laxai Pharma, Ltd. (LAXAF)
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ)
Business
Evotec SE functions as a dedicated partner for integrated drug discovery and development across the global pharmaceutical and biotechnology sectors. The company provides comprehensive solutions from target identification through clinical advancement, leveraging its extensive platforms in small molecules, biologics, and cell therapies. Evotec's expertise spans a broad range of therapeutic categories, including oncology, neurological and metabolic conditions, autoimmune disorders, inflammation, pain, infectious diseases, and rare diseases, among others. The company's unique approach integrates cutting-edge technologies like proprietary molecular patient databases, PanOmics, iPSC-based disease modeling, and AI/ML-driven discovery platforms to enhance the probability of success in developing new medicines. Evotec maintains a wide network of collaborations, partnering with major pharmaceutical companies, biotechnology firms, and academic institutions. Recent alliances include a significant agreement with Sandoz AG for the sale of its Just – Evotec Biologics Toulouse site, potentially yielding over US$650 million plus future royalties on biosimilars. The company also expanded its strategic neuroscience partnership with Bristol Myers Squibb, receiving milestone payments for scientific progress and IND acceptances. Additionally, Evotec forged a technology development partnership with Novo Nordisk in cell therapy. In April 2025, Evotec unveiled a new strategy, "Priority Reset," to streamline its business model, reinforce its technology and science leadership, and target sustainable profitable growth, aiming for annualized gross savings. Originally incorporated in 1993, the company transitioned its name from Evotec AG to Evotec SE in April 2019 and is headquartered in Hamburg, Germany.